![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
MK-5172, a Second Generation HCV NS3/4A Protease Inhibitor is Active Against Common Resistance Associated Variants (RAVs) and Exhibits Cross-Genotype Activity
|
|
|
Reported by Jules Levin
HEP DART 2011, December 4-8th 2011, Kauai, HI, USA
RJO Barnard, D Graham, A Acosta, Z Guo, JA Howe, R Ogert, M Miller, D Hazuda, D Olsen, S Ludmerer, JM Strizki
Merck & Co., Inc., Whitehouse Station, NJ, USA
![AASLD1.gif](../images/120611/120611-7/AASLD1.gif)
![AASLD2.gif](../images/120611/120611-7/AASLD2.gif)
![AASLD3.gif](../images/120611/120611-7/AASLD3.gif)
![AASLD4.gif](../images/120611/120611-7/AASLD4.gif)
![AASLD5.gif](../images/120611/120611-7/AASLD5.gif)
![AASLD6.gif](../images/120611/120611-7/AASLD6.gif)
![AASLD7.gif](../images/120611/120611-7/AASLD7.gif)
![AASLD8.gif](../images/120611/120611-7/AASLD8.gif)
![patient5.gif](../images/120611/120611-7/patient5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|